News coverage about Pernix Therapeutics (NASDAQ:PTX) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pernix Therapeutics earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 45.5041953002352 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Pernix Therapeutics (NASDAQ PTX) traded down $0.11 during trading hours on Tuesday, hitting $2.60. 101,400 shares of the company were exchanged, compared to its average volume of 397,166. The company has a current ratio of 0.99, a quick ratio of 0.91 and a debt-to-equity ratio of -0.80. Pernix Therapeutics has a 52 week low of $1.83 and a 52 week high of $7.15.
Pernix Therapeutics Company Profile
Pernix Therapeutics Holdings, Inc is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas.
Receive News & Ratings for Pernix Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.